Jean‐yves Douillard
#142,228
Most Influential Person Now
Jean‐yves Douillard's AcademicInfluence.com Rankings
Jean‐yves Douillardmedical Degrees
Medical
#2594
World Rank
#3024
Historical Rank
Oncology
#164
World Rank
#170
Historical Rank
Jean‐yves Douillardphilosophy Degrees
Philosophy
#7471
World Rank
#10691
Historical Rank
Logic
#4515
World Rank
#5824
Historical Rank
Download Badge
Medical Philosophy
Why Is Jean‐yves Douillard Influential?
(Suggest an Edit or Addition)Jean‐yves Douillard's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. (2003) (2937)
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016) (2368)
- Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. (2013) (1947)
- Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. (2008) (1928)
- Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. (2010) (1675)
- Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. (2006) (1410)
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial (2008) (1275)
- Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. (2006) (1169)
- Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma (1998) (909)
- Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. (1994) (835)
- Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. (1991) (810)
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. (2014) (764)
- Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † (2017) (577)
- Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. (2010) (497)
- ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. (2019) (442)
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. (2020) (432)
- ESMO-Magnitude of Clinical Benefit Scale version 1.1 (2017) (396)
- Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. (2014) (363)
- 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. (2014) (362)
- Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. (2002) (359)
- First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study (2013) (350)
- ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. (2013) (344)
- Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. (2002) (337)
- Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. (2008) (320)
- Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma. (1983) (317)
- Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. (2007) (314)
- Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. (1998) (308)
- Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. (2014) (291)
- Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. (2009) (274)
- Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. (2015) (263)
- Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. (2011) (262)
- Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. (2013) (262)
- Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer. (2016) (261)
- Astro plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: A randomized study of 353 patients (1991) (258)
- Gefitinib Treatment in EGFR Mutated Caucasian NSCLC (2014) (252)
- Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. (1992) (246)
- Immunoscintigraphy of colon carcinoma. (1984) (236)
- Potential regional differences for the tolerability profiles of fluoropyrimidines. (2008) (225)
- Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. (2012) (221)
- Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. (2008) (217)
- Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study (2002) (217)
- Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection. (2015) (211)
- Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation (2010) (199)
- European Society for Medical Oncology (ESMO) position paper on supportive and palliative care (2018) (182)
- Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. (2008) (179)
- Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie. (2004) (177)
- A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). (2009) (168)
- ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association (2005) (168)
- Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients. (2006) (166)
- Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. (2005) (164)
- Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. (2009) (161)
- Global cancer control: responding to the growing burden, rising costs and inequalities in access (2018) (159)
- Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies (2017) (159)
- Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. (2008) (156)
- Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. (2009) (156)
- Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. (1994) (153)
- Intrapleural treatment with recombinant gamma‐interferon in early stage malignant pleural mesothelioma (1994) (152)
- Capecitabine plus oxaliplatin (XELOX) versus 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancer (2011) (151)
- Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. (2006) (147)
- Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS (2019) (146)
- Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). (2003) (140)
- A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens (2011) (134)
- A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. (2002) (124)
- Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action. (2013) (123)
- ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. (2019) (123)
- Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial (2006) (120)
- Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT) (2018) (114)
- Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. (2014) (109)
- Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer. (2000) (109)
- Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. (2016) (106)
- Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers (2016) (102)
- Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study. (1996) (101)
- Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials. (2015) (100)
- ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. (2019) (99)
- Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). (2006) (92)
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. (2020) (92)
- Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST): PRS-02 (2007) (91)
- Enzyme-linked immunosorbent assay for screening monoclonal antibody production using enzyme-labeled second antibody. (1983) (90)
- Small Cell Carcinoma of the Esophagus: Analysis of 10 Cases and Review of the Published Data (2000) (89)
- 10LBA Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial (2009) (89)
- Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape. (1999) (89)
- A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802) (2005) (88)
- ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer (2020) (84)
- Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. (2015) (83)
- Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project (2018) (82)
- Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib (2011) (82)
- Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC) (2007) (82)
- Comparison of Docetaxel- and Vinca Alkaloid–Based Chemotherapy in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis of Seven Randomized Clinical Trials (2007) (82)
- Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie. (1998) (81)
- Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study. (1997) (80)
- An interleukin 2/sodium butyrate combination as immunotherapy for rat colon cancer peritoneal carcinomatosis. (1994) (80)
- Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients. (2013) (79)
- Enzyme-linked immunosorbent assay for screening monoclonal antibody production: use of intact cells as antigen. (1980) (79)
- Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. (2010) (77)
- Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy. (2010) (77)
- Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). (2014) (76)
- Prognostic and Predictive Effect of TP53 Mutations in Patients with Non–Small Cell Lung Cancer from Adjuvant Cisplatin–Based Therapy Randomized Trials: A LACE‐Bio Pooled Analysis (2016) (75)
- Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. (2017) (74)
- Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. (2019) (68)
- Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens. (2010) (68)
- Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial. (2010) (68)
- Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC). (2013) (66)
- Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. (2001) (66)
- Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. (2015) (66)
- Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer. (1998) (65)
- JSCO/ESMO/ASCO/JSMO/TOS: International expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. (2020) (65)
- Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. (2019) (62)
- Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer. (1996) (60)
- Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE) (2021) (60)
- The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). (2014) (58)
- Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie (2005) (58)
- Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial. (1999) (58)
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. (2020) (56)
- A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. (2016) (56)
- Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. (2015) (55)
- Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non–Small-Cell Lung Cancer (2014) (54)
- Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study (2006) (54)
- Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. (2015) (52)
- Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy. (2003) (52)
- Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment (2011) (51)
- RAS mutations in colorectal cancer. (2013) (51)
- ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. (2021) (51)
- Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). (2013) (48)
- High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy. (1991) (48)
- Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials. (2009) (48)
- Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? (2007) (47)
- Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5- FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC) (2007) (47)
- A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis. (1994) (47)
- ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer (2020) (47)
- Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials (2013) (46)
- [Immunotherapy for non-small cell lung cancer--novel approaches to improve patient outcome]. (2013) (45)
- A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial). (2013) (44)
- Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non–Small-Cell Lung Cancer (2015) (44)
- A phase 2 study of a novel transforming growth factor-beta (TGF-{beta}1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC). (2014) (44)
- The care of adolescents and young adults with cancer: results of the ESMO/SIOPE survey (2017) (43)
- Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST) (2008) (43)
- Radioimmunoassay of the CA 12 5 antigen in ovarian carcinomas: advantages compared with CA 19-9 and CEA. (1984) (43)
- Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients. (2002) (41)
- Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients (2016) (41)
- Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer. (2020) (41)
- Resection of Hepatic and Pulmonary Metastases in Patients With Colorectal Cancer (2001) (41)
- Toxicity of irinotecan in patients with colorectal cancer. (2001) (40)
- Phase III study of vinflunine versus docetaxel in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a platinum-containing regimen (2007) (40)
- [Breast cancer in the early stage]. (2012) (39)
- PANERB study: Panitumumab after cetuximab-based regimen failure. (2010) (39)
- Effect of Primary Tumor Location on Second‐ or Later‐line Treatment Outcomes in Patients With RAS Wild‐type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies (2018) (39)
- Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan. (2012) (39)
- Selective modification of NMR relaxation time in human colorectal carcinoma by using gadolinium-diethylenetriaminepentaacetic acid conjugated with monoclonal antibody 19-9. (1986) (38)
- Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial. (2013) (38)
- Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study. (2005) (37)
- Anti-idiotypic antibodies to monoclonal antibody CO17-1A. (1986) (37)
- Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer (2013) (37)
- Pilot study of neoadjuvant ifosfamide, cisplatin, and etoposide in locally advanced non-small cell lung cancer. (1990) (36)
- Concomitant chemoradiotherapy followed, where feasible, by surgery for cancer of the esophagus. (1997) (36)
- A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH pts. (2006) (35)
- Human T(H)17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-γ-secreting cells as they differentiate into effector T cells in vivo. (2012) (34)
- Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). (2014) (34)
- Summary report of the Standards, Options and Recommendations for the management of patients with non-small-cell lung carcinoma (2000) (2003) (34)
- Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial analysis by epidermal growth factor receptor (EGFR) tumor staining. (2010) (33)
- Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer (2009) (32)
- Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. (2017) (32)
- Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study (2001) (32)
- Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first line metastatic colorectal cancer (mCRC). (2011) (32)
- Monoclonal antibodies specific immunotherapy of gastrointestinal tumors. (1986) (31)
- A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): Final PFS results (2008) (31)
- An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer. (2011) (31)
- Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer. (2000) (30)
- Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study. (2000) (30)
- Immunotherapy for Non-small Cell Lung Cancer: Novel Approaches to Improve Patient Outcome (2011) (30)
- Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel. (2015) (29)
- Prediction of survival benefits from progression-free survival in patients with advanced non small cell lung cancer: Evidence from a pooled analysis of 2,838 patients randomized in 7 trials (2008) (29)
- How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials (2017) (29)
- Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study (2017) (28)
- Phase III study (PRIME/20050203) of panitumumab (pmab) with FOLFOX compared with FOLFOX alone in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Pooled safety data (2008) (28)
- Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer (2000) (28)
- Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study. (2012) (27)
- Final skin toxicity (ST) and patient-reported outcomes (PRO) results from PRIME: A randomized phase III study of panitumumab (pmab) plus FOLFOX4 (CT) for first-line metastatic colorectal cancer (mCRC). (2012) (27)
- Negative influence of delayed surgery on survival after preoperative radiotherapy in rectal cancer. (2001) (27)
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. (2020) (27)
- Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study (2017) (27)
- Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib (2011) (26)
- A phase II study of RAD001 (R) (everolimus) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I) (2007) (26)
- Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial. (2011) (26)
- A phase III randomised trial of LV 5 FU 2 1 irinotecan versus LV 5 FU 2 alone in adjuvant high-risk colon cancer ( FNCLCC Accord 02 / FFCD 9802 ) (2009) (25)
- Evaluation of Individual Codon 12 and 13 Mutant (MT) KRAS Alleles as Prognostic and Predictive Biomarkers of Response to Panitumumab (pmab) in Patients with Metastatic Colorectal Cancer (mCRC) (2011) (25)
- Challenging the platinum combinations in the chemotherapy of NSCLC. (2002) (25)
- Adjuvant chemotherapy for non-small-cell lung cancer: it does not always fade with time. (2010) (25)
- Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. (2004) (24)
- Focus on the controversial activation of human iNKT cells by 4-deoxy analogue of KRN7000. (2009) (24)
- Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma. (2012) (23)
- Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer. (1994) (23)
- Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough? (2019) (23)
- Human anti-murine immunoglobulin responses and immune functions in cancer patients receiving murine monoclonal antibody therapy. (1991) (23)
- Irinotecan in first line therapy of elderly and non-elderly patients with metastatic colorectal cancer: Meta-analysis of four trials investigating 5-FU and irinotecan. (2006) (23)
- A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer. (2000) (23)
- Immune function of patients with gastrointestinal carcinoma after treatment with multiple infusions of monoclonal antibody 17.1A. (1987) (22)
- Cost Consequences of Adjuvant Capecitabine, Mayo Clinic and de Gramont Regimens for Stage III Colon Cancer in the French Setting (2008) (22)
- Cost-Minimisation Analysis in First-Line Treatment of Metastatic Colorectal Cancer in France: XELOX versus FOLFOX-6 (2011) (22)
- The Role of UFT in Metastatic Colorectal Cancer (2009) (22)
- Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice. (2000) (22)
- Chronopharmacokinetics of Oral Tegafur and Uracil in Colorectal Cancer Patients (2008) (21)
- Monoclonal antibodies to a rat colon carcinoma: model for monoclonal antibody therapy of solid tumors. (1989) (21)
- FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study. (2014) (21)
- Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer (2007) (20)
- ‘A phase II study of oral uracil/ftorafur (UFT®) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer’ (2005) (20)
- A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics. (2013) (19)
- Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules (2017) (19)
- AZD6244 (ARRY-142886) versus capecitabine (CAP) in patients (pts) with metastatic colorectal cancer (mCRC) who have failed prior chemotherapy (2008) (19)
- 3-fluoro- and 3,3-difluoro-3,4-dideoxy-KRN7000 analogues as new potent immunostimulator agents: total synthesis and biological evaluation in human invariant natural killer T cells and mice. (2012) (19)
- Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial. (2012) (19)
- Prognostic and predictive effects of KRAS mutation subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study. (2012) (19)
- Impact on survival of primary tumor resection in patients with colorectal cancer and unresectable metastasis: Pooled analysis of individual patients' data from four randomized trials. (2012) (18)
- Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study (2018) (18)
- Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (2018) (18)
- Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status (2015) (18)
- Subcutaneous interleukin‐2 and interferon α in the treatment of patients with metastatic renal cell carcinoma—Less efficacy compared with intravenous interleukin‐2 and interferon α (2002) (17)
- Comparative characteristics of 17-1A and GA-733 monoclonal antibodies for immunoscintigraphic application. (1986) (17)
- Defect in lectin-induce interleukin 2 (IL-2) production by peripheral blood lymphocytes of patients with Hodgkin's Disease (1985) (17)
- Pr3 ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation in completely resected (stage I–III) non small cell lung cancer (NSCLC) patients (pts) (2005) (17)
- A Phase II Study with 5-Fluorouracil, Folinic Acid and Oxaliplatin (FOLFOX-4 Regimen) in Patients with Metastatic Renal Cell Carcinoma (2002) (17)
- Apoptosis induced by sodium butyrate treatment increases immunogenicity of a rat colon tumor cell line (2004) (17)
- Immunohistochemical antigenic expression and in vivo tumor uptake of monoclonal antibodies with specificity for tumors of the gastrointestinal tract. (1986) (17)
- Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST). (2010) (17)
- Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer. (1999) (16)
- Challenging the platinum combinations: Docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer. (2001) (16)
- Panitumumab‐based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials (2019) (16)
- LACE‐Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry‐based Biomarkers in Resected Non–small‐cell Lung Cancer (2019) (16)
- Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients with Elevated CEA. (2020) (16)
- Treatment sequence of synchronously (liver) metastasized colon cancer. (2016) (15)
- Non-small cell lung cancer, locally advanced (2012) (15)
- Updated efficacy findings from the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes’ C colon cancer (2005) (15)
- 2LB Phase III, randomized, open-label, parallel-group study of oral gefitinib (IRESSA) versus intravenous docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who have previously received platinum- based chemotherapy (INTEREST) (2007) (15)
- Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie. (2002) (15)
- Patterns of locoregional failure in locally advanced non-small cell lung cancer treated with definitive conformal radiotherapy: Results from the Gating 2006 trial. (2017) (15)
- Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial (2016) (15)
- 42 Phase II study of BAY 43-9006 in patients with advanced hepatocellular carcinoma (HCC) (2004) (15)
- Negative influence of delayed surgery on survival after preoperative radiotherapy in rectal cancer (2006) (14)
- High-dose interleukin-2 two days a week for metastatic renal cell carcinoma: a FNCLCC multicenter study. (1994) (14)
- The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012 (2013) (14)
- Immunotherapy of gastrointestinal cancer with monoclonal antibodies (1986) (14)
- Lace-Bio Pooled Analysis of the Prognostic and Predictive Value of TP53 Mutations in Completely Resected Non Small Cell Lung Cancer (NSCLC) (2012) (13)
- Overall survival (OS) analysis from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC). (2013) (13)
- Immunization against a rat colon carcinoma by sodium butyrate-treated cells but not by interleukin 2-secreting cells. (1995) (13)
- The global landscape of treatment standards for breast cancer. (2021) (13)
- Efficacy and safety of FOLFIRINOX in patients with metastatic pancreatic cancer. (2014) (13)
- Phase II study of Interferon-α and all-trans retinoic acid in metastatic renal cell carcinoma (1998) (13)
- Squamous cell carcinoma of the esophagus. Treatment by combined vincristine‐methotrexate plus folinic acid rescue and cisplatin before radiotherapy (1985) (13)
- ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy (2020) (13)
- Chemotherapy effect on locally advanced non small cell lung carcinoma: A randomized study on 353 patients (1990) (13)
- Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO) (2016) (12)
- Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts) (2004) (12)
- Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared with FOLFOX4 alone as first line treatment (tx) for metastatic colorectal cancer (mCRC): Results by Eastern Cooperative Oncology Group (ECOG) performance status (PS). (2011) (12)
- Karyotypic and phenotypic variations between cell lines established from a primary colorectal tumour and two corresponding metastases from one patient. (1993) (12)
- Prognostic value of early objective tumor response (EOTR) to first-line systemic therapy in metastatic colorectal cancer (mCRC): Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database. (2013) (12)
- Adjuvant chemotherapy for colon cancer: a confusing area! (2005) (12)
- Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): Assessment as prognostic and predictive biomarkers of response to panitumumab (pmab). (2012) (12)
- Relationship between sensitivity to natural killer cells and MHC class‐I antigen expression in colon carcinoma cell lines (1992) (11)
- Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer? (2008) (11)
- Interleukin‐2/sodium butyrate treatment cures rats bearing liver tumors after acquired 5‐fluorouracil resistance (1998) (11)
- Bevacizumab Efficacy Is Influenced by Primary Tumor Resection in First-Line Treatment of Metastatic Colorectal Cancer in a Retrospective Multicenter Study. (2016) (11)
- A Clinical Pharmacokinetic Analysis of Tegafur-Uracil (UFT) Plus Leucovorin Given in a New Twice-Daily Oral Administration Schedule (2007) (11)
- A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors (2010) (11)
- Care of adolescents and young adults with cancer in Asia: results of an ESMO/SIOPE/SIOP Asia survey (2019) (11)
- Immunoglobulin class and immunoglobulin G subclass analysis of human anti-mouse antibody response during monoclonal antibody treatment of cancer patients. (1990) (10)
- Efficacy of 5FU + cisplatin (FUP) compared to bolus 5FU (FU) in advanced pancreatic carcinoma (APC) (1999) (10)
- International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non–Small Cell Lung Cancer: Realities and Hopes (2016) (10)
- Safety and Resource Utilization by Non-small Cell Lung Cancer Histology: Results from the Randomized Phase III Study of Pemetrexed Plus Cisplatin versus Gemcitabine Plus Cisplatin in Chemonaïve Patients with Advanced Non-small Cell Lung Cancer (2010) (10)
- BRAF V600E Mutation in First-line Metastatic Colorectal Cancer: an Analysis of Individual Patient Data from the ARCAD Database. (2021) (10)
- 547PIMPACT OF BASELINE AGE ON EFFICACY AND SAFETY OF FIRST-LINE PANITUMUMAB (PMAB) + FOLFOX4 VS FOLFOX4 TREATMENT. (2014) (10)
- [Standards, Options and Recommendations for the management of non-small cell lung carcinoma patients]. (2003) (10)
- A phase II trial of radiochemotherapy with daily carboplatin, after induction chemotherapy (carboplatin and etoposide), in locally advanced nonsmall-cell lung cancer: final analysis. (1997) (10)
- A Phase II Trial of Raltitrexed (Tomudex®) in Advanced Pancreatic and Biliary Carcinoma (2005) (9)
- Phase III, randomized, open-label study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): Findings from an interim safety analysis (2005) (9)
- Invincible Athletics program: aerobic exercise and performance without strain. (1996) (9)
- Comparison of docetaxel and vinca alkaloid, alone or in combination with other chemotherapy agents, in the first-line treatment of advanced non-small cell lung cancer (NSCLC): A meta-analysis. (2006) (9)
- Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC): NCIC-CTG BR.18. (2004) (9)
- [Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer]. (1996) (9)
- Value of Contrast-Enhanced Ultrasound Quantification Criteria for Identifying Patients not Responding to Bevacizumab-Based Therapy for Colorectal Liver Metastases (2017) (9)
- 2nd ESMO Consensus Conference on Lung Cancer : non-small-cell lung cancer first-line/second and further lines in advanced disease (2014) (9)
- Cost-minimization analysis of a phase III study of capecitabine + oxaliplatin (XELOX) vs. infusional 5-FU/LV + oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (MCRC) in the French setting (2007) (9)
- Randomized phase III trial of gemcitabine/cisplatin (GC) and protein kinase C α (PKCα) antisense oligonucleotide aprinocarsen in patients (pts) with advanced stage non-small cell lung cancer (NSCLC) (2005) (9)
- 3,4-Dideoxy-3,3,4,4-tetrafluoro- and 4-OH epimeric 3-deoxy-3,3-difluoro-α-GalCer analogues: Synthesis and biological evaluation on human iNKT cells stimulation. (2019) (8)
- MAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA NSCLC. (2011) (8)
- 9003 Response and progression-free survival in 1006 patients with known EGFR mutation status in phase III randomized trials of gefitinib in individuals with non-small cell lung cancer (2009) (8)
- EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies (2020) (8)
- Old drug, new clinical use, no man’s land for the indication: an awareness call from European experts (2020) (8)
- Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial†. (2015) (8)
- [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer]. (2016) (8)
- Resource utilization by non-small cell lung cancer histology: Results from the randomized, phase III trial of pemetrexed/cisplatin versus gemcitabine/cisplatin (2008) (8)
- Vinflunine (VFL) in combination with gemcitabine (GEM) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts): Preliminary results of the phase I and pharmacokinetic study (2005) (8)
- Pharmacokinetic study of radiolabeled anti-colorectal carcinoma monoclonal antibodies in tumor-bearing nude mice (2004) (7)
- 68O EFFICACY, SAFETY AND TOLERABILITY RESULTS FROM A PHASE IV, OPEN-LABEL, SINGLE ARM STUDY OF 1ST-LINE GEFITINIB IN CAUCASIAN PATIENTS (PTS) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC) (2013) (7)
- Irinotecan-based regimens in the adjuvant therapy of colorectal cancer. (2005) (7)
- Targeting the target: a step forward for the treatment of non-small-cell lung cancer. (2010) (7)
- AbstractPlenary 3: Impact of Radiation on Survival After Complete Resection of Non–Small-Cell Lung Cancer: Descriptive Analysis in the Randomized Adjuvant Chemotherapy Trial, ANITA 1 (2006) (7)
- Combined radiation and chemotherapy for unresectable non-small cell lung carcinoma. (1994) (7)
- Consensus Conference on Lung Cancer : early-stage non-small-cell lung cancer consensus on diagnosis , treatment and follow-up (2014) (7)
- Comparison between 131I and 111In as radiolabels for monoclonal antibodies in immunoscintigraphy of tumor bearing nude mice. (1986) (6)
- Fortis-M, a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Oral Talactoferrin Alfa with Best Supportive Care in Patients with Advanced Non-Small Cell Lung Cancer Following Two or More Prior Regimens- by the Fortis-M Study Group (2012) (6)
- Defect in lectin-induced interleukin 2 (IL-2) production by peripheral blood lymphocytes of patients with Hodgkin's disease. (1985) (6)
- UFT/LV combination based regimens with oxaliplatin or irinotecan as first line treatment for patients (pts) with non resectable metastatic colorectal cancer(MCRC): Results of two multicentric phase II trials. (2004) (6)
- Efficacy and safety of nintedanib (NIN)/docetaxel (DOC) in patients with lung adenocarcinoma: Further analyses from the LUME-Lung 1 study (2016) (6)
- Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer (CRC): An analysis of 18,399 patients in the ARCAD database. (2020) (6)
- Quality to rely on: meeting report of the 5th Meeting of External Quality Assessment, Naples 2016 (2016) (6)
- ZD0473 combined with other chemotherapeutic agents for the treatment of solid malignancies. (2002) (6)
- [Use of radio-labelled monoclonal antibodies for the scintigraphic detection of human colorectal cancers]. (1983) (6)
- Analysis of the state of differentiation of two rat colon carcinoma clones with distinct tumorigenic properties. (1991) (6)
- Cancers broncho-pulmonaires (2005) (6)
- O126 EVALUATION OF LY2157299 MONOHYDRATE (LY), A TGF-β RECEPTOR I KINASE INHIBITOR, IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: PHASE 2 STUDY RESULTS OF SAFETY, EFFICACY AND PK/PD (2014) (6)
- Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database. (2013) (6)
- Randomized dose comparison phase II study of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) in patients with advanced hepatocellular carcinoma (HCC). (2013) (6)
- [Interleukin-2 and interferon in metastatic kidney cancer. Experience of the French Immunotherapy Group]. (2002) (5)
- MC13-0022 Resection rates and survival in patients with wild-type KRAS/NRAS metastatic colorectal cancer and liver metastases: Data from the PRIME study (2013) (5)
- First-in-man study of tafluposide, a novel inhibitor of topoisomerase I and II (2007) (5)
- Irinotecan: a new treatment in metastatic colorectal cancer (2000) (5)
- Q-TWiST analysis of panitumumab plus FOLFOX4 versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer (2016) (5)
- Panerb Study: Which Category of Patients, Suffering from Metastatic Colorectal Cancer, Can Benefit From Panitumumab Treatment After Cetuximab-Based Regimen Failure? (2012) (5)
- C1-04: A phase II study of RAD001 (everolimus) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I) (2007) (5)
- 3535 POSTER Phase II trial investigating the efficacy and safety of sunitinib in patients with unresectable hepatocellular carcinoma (HCC) (2007) (5)
- Quality of life (QoL) during first-line treatment with FOLFOX4 with or without panitumumab (pmab) in RAS wild-type (WT) metastatic colorectal carcinoma (mCRC). (2015) (5)
- Therapeutic strategies for colorectal cancer in Europe and the United States: focus on chemotherapy for advanced colorectal cancer (2002) (5)
- Randomised phase II study of BMS-275291 versus placebo in patients (pts) with stage IIIb or IV non small cell lung cancer (NSCLC) receiving paclitaxel + carboplatin (PC): National Cancer Institute of Canada clinical trials group (NCIC CTG) br.18 (2001) (5)
- Docetaxel in combined-modality treatment of inoperable locally or regionally advanced lung cancer. (2004) (5)
- Antiangiogenic-specific adverse events (AEs) in patients with non-small cell lung cancer (NSCLC) treated with nintedanib (N) and docetaxel (D). (2014) (5)
- Repeat hepatectomy for colorectal liver metastases. (2005) (5)
- E46Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial) (2015) (5)
- Irinotecan/5-FU/FA (I-FU) or 5-FU/FA (FU) first-line therapy in older and younger patients with metastatic colorectal cancer: Combined analysis of 2,691 patients in randomized controlled trials (2007) (5)
- 292 Tegafox, a new combination of UFT/LV and oxaliplatin as first line treatment for patients (pts) with non resectable metastatic colorectal cancer (CRC): results of a completed multicenter phase II (2003) (5)
- Concurrent treatments and induction treatments for unresectable tumors. (1997) (5)
- Enzyme-linked immunosorbent assay to monitor colorectal carcinoma patients treated with a monoclonal antibody (17-1A). (1985) (5)
- Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts). (2004) (5)
- Fotemustine: French multicenter phase II study in 67 patients with advanced non small cell lung carcinoma (NSCLC) (1991) (4)
- O-0017 Randomized Phase II Study Evaluating Ufox Plus Cetuximab Versus Folfox4 Plus Cetuximab as First-Line Therapy in Metastatic Colorectal Cancer: Future (2012) (4)
- [Standards, options and recommendations for the management of locally advanced non small cell lung carcinoma]. (2001) (4)
- 92 CPT 11 (Irinotecan) in pretreated small cell lung cancer (SCLC): A phase II study in patients progressing after a first response (preliminary results) (1995) (4)
- Pharmacokinetic studies of mouse monoclonal antibodies to a rat colon carcinoma: I. Comparison of biodistribution in normal rats, syngeneic tumor-bearing rats, or tumor-bearing nude mice. (1990) (4)
- Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment. (2011) (4)
- Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy ± biologic: Findings from 9,092 pts in the ARCAD database. (2017) (4)
- 471PEFFECT OF NINTEDANIB (BIBF 1120) COMBINED WITH STANDARD 2ND-LINE DOCETAXEL IN NSCLC PATIENTS WHO RECEIVED PRIOR PEMETREXED IN LUME-LUNG 1: A RANDOMISED, PLACEBO-CONTROLLED PHASE III TRIAL. (2014) (4)
- Phase II study of IV Vinflunine (VFL) as second line treatment of patients (pts) with advanced non-small-cell lung cancer (NSCLC) previously treated with a platinum based regimen. Final results (2004) (4)
- 1096 Preliminary report of a phase II study of docetaxel (taxotere® and cisplatin in advanced non small cell lung cancer (NSCLC) (1995) (4)
- Safety and quality of life (QoL) findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5-FU/LV + O (FOLFOX-6) in metastatic colorectal cancer (MCRC) (2007) (4)
- Humoral and cellular responses of colorectal cancer patients treated with monoclonal antibodies and interferon γ (2005) (4)
- Phase I Trial of Gemcitabine Combined with Capecitabine and Erlotinib in Advanced Pancreatic Cancer: A Clinical and Pharmacological Study (2012) (4)
- A new tumor-associated antigen expressed on breast carcinomas, defined by monoclonal antibody BCA 227. (1991) (4)
- 1089 Improved safety of capecitabine vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT phase III study) (2003) (4)
- B3-05: Meta-analysis comparing docetaxel and vinca-alkaloids in the first-line treatment of NSCLC. Comparison of results based on individual patient data, study report data, and published data (2007) (4)
- Microsatellite instability and mismatch repair genes in colorectal cancer: useful tools for managing patients and counseling their relatives. (2010) (4)
- Phase II study of interferon-alpha and all-trans retinoic acid in metastatic renal cell carcinoma. (1998) (4)
- MAGRIT phase III trial in adjuvant NSCLC: MAGE-A3 gene expression frequency on the first 2150 patients screened and demographics of first patients randomized (2009) (4)
- 6507 ORAL Phase III study of IV vinflunine (VFL) versus IV docetaxel (DTX) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with a platinum-containing regimen (2007) (4)
- PD-031An exploratory study-level meta-analysis assessing the impact of early tumour shrinkage on overall survival in patients with RAS wild-type metastatic colorectal cancer receiving first-line treatment in three randomised panitumumab trials (2016) (4)
- Survival outcomes in patients (pts) with KRAS/NRAS (RAS) wild-type (WT) metastatic colorectal cancer (mCRC) and non-liver-limited disease (non-LLD): Data from the PRIME study. (2014) (4)
- Can interleukin-2 reverse anthracyclin chemoresistance in metastatic soft tissue sarcoma patients. Results of a prospective phase II clinical trial. (2001) (4)
- 919 Clinically meaningful improvement in disease-related symptoms by gefitinib (‘Iressa’, ZD1839) in patients with advanced non-small-cell lung cancer: relationship between lung cancer subscale scores and radiographic response and survival (2003) (4)
- Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1 (2020) (4)
- MAGE-A3 cancer immunotherapeutic in resected stage IB-III NSCLC patients with or without sequential or concurrent chemotherapy. (2012) (4)
- What is the benefit for patients suffering from metastatic colorectal cancer (mCRC) after bevacizumab-based regimen (BBR), cetuximab-based regimen (CBR), and panitumumab (P)? (2011) (3)
- Comparison of SPECT imaging using monoclonal antibodies with computed tomography (CT) and ultrasonography (US) for detection of recurrences of colorectal carcinoma: A prospective clinical study (1985) (3)
- ‘Tomudex’ (raltitrexed) plus oxaliplatin (Eloxatin) in previously untreated metastatic colorectal cancer (MCRC) patients: an active combination (1999) (3)
- Survival outcomes in the PRIME study for patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC), by baseline Eastern Cooperative Oncology Group (ECOG) performance status (PS). (2014) (3)
- [2000 Standards, Options and Recommendations for prognostic value of oncogenes and tumor suppressor genes in non small cell lung cancer]. (2002) (3)
- 6095 POSTER Randomized, Open-label, Phase 3 Study of Panitumumab (Pmab) With FOLFOX4 Vs FOLFOX4 Alone as 1st-line Treatment for Metastatic Colorectal Cancer (mCRC) – the Role of Hypomagnesemia (Hypomag) on Efficacy (2011) (3)
- Impact of depth of response (DpR) on survival in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line panitumumab + FOLFOX4 vs FOLFOX4 (2016) (3)
- Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years (2022) (3)
- Body, Mind, and Sport: The Mind-Body Guide to Lifelong Health, Fitness, and Your Personal Best (1994) (3)
- [Adjuvant chemotherapy for non-small cell lung cancer--which agents for which patients?]. (2005) (3)
- [Efficacy and safety of gefitinib or docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed previous platinum-based first-line chemotherapy]. (2011) (3)
- Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial. (2015) (3)
- 473PPRIOR TAXANE USE IN THE LUME-LUNG 1 PHASE III TRIAL AND THE EFFECT ON OUTCOME FOLLOWING 2ND-LINE TREATMENT WITH NINTEDANIB (BIBF 1120) AND DOCETAXEL IN PATIENTS WITH ADVANCED NSCLC. (2014) (3)
- Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after one prior chemotherapy regimen: Results of Lume-Lung 1, a randomized, double-blind, phase III trial. (2013) (3)
- Concurrent losses of skeletal muscle mass, adipose tissue and bone mineral density during bevacizumab / cytotoxic chemotherapy treatment for metastatic colorectal cancer. (2020) (3)
- Safety summary of panitumumab (pmab) in combination with chemotherapy (ctx) from four clinical trials in patients (pts) with metastatic colorectal cancer (mCRC). (2009) (3)
- Update on European adjuvant trials with irinotecan for colorectal cancer. (2002) (3)
- LBA52Randomized double blind phase IIb trial in advanced NSCLC patients who did not progress after first line platinum based chemotherapy: Vx-001, a therapeutic cancer vaccine, vs placebo as maintenance therapy (2017) (3)
- 52 Rapid and durable objective responses in patients with advanced non-small-cell lung cancer in phase II trials (IDEAL 1 and IDEAL 2) treated with gefitinib (2003) (3)
- Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT) (2020) (3)
- Comparative pharmacokinetics of a murine monoclonal antibody to a rat colon tumor in rats and nude mice. (1990) (3)
- Quality-adjusted survival in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line therapy with panitumumab plus FOLFOX versus FOLFOX alone in the PRIME trial. (2015) (3)
- Phase II study with Taxol® (paclitaxel) and Gemzar® (gemcitabine) in metastatic non-small cell lung cancer (NSCLC) (2000) (3)
- Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty (2019) (2)
- CETUFTIRI, a new combination of UFT with leucovorin (LV), irinotecan, and cetuximab as first-line treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC): Preliminary results from a multicenter phase II trial (2007) (2)
- 5FU-leucovorin (5FU/LV) with or without irinotecan (CPT-11) in stages II-III rectal cancers: Preliminary safety analysis of the French Intergroup R98 phase III trial (2004) (2)
- Preliminary results of a randomized study on first and second line chemotherapy strategy in stage IV non-small cell lung cancer (NSCLC), assessing docetaxel (D) and cisplatin (C) until progressive disease (PD) then vinorelbine (V) versus V-C until PD then D (2000) (2)
- Pharmacokinetic studies of mouse monoclonal antibodies to a rat colon carcinoma. II : Comparative biodistribution of intact antibodies and F(ab')2 fragments in normal rats, syngeneic tumor-bearing rats, and tumor-bearing nude mice (1991) (2)
- Navelbine (NVB)-cisplatin (CDDP) induction chemotherapy (ICT) followed by radiation with or without daily carboplatin (CBDCA) in locally advanced unresectable non small cell lung cancer: Intermediate analysis of a french, multicenter phase III randomized trial (2000) (2)
- EC3 COST-MINIMIZATION ANALYSIS OF CAPECITABINE + OXALIPLATIN (XELOX) VS. INFUSIONAL 5-FU/LV + OXALIPLATIN (FOLFOX-6) AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) IN THE FRENCH SETTING (2007) (2)
- [Optimizing good use and costs of anticancer drugs: A French inter regional study of the Observatory of Cancer]. (2013) (2)
- Tumor growth over time in patients with non-small cell lung cancer (NSCLC) of adenocarcinoma histology (ACH) treated with nintedanib and docetaxel or placebo and docetaxel: Analysis of data from the LUME-Lung 1 (LL1) study. (2015) (2)
- 223 Docetaxel in combination with vinorelbine in chemotherapy naive patients with metastatic or unresectable non-small cell lung cancer (NSCLC): Preliminary results of a phase I study (1997) (2)
- Abstract C261: Pharmacokinetics (PK) and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF-β) receptor I kinase inhibitor LY2157299 monohydrate (LY) in hepatocellular carcinoma (HCC) compared to glioma patients. (2013) (2)
- [Problems posed by secondary peritoneal carcinosis of digestive origin]. (1994) (2)
- MC13-0024 Impact of post-progression anti-vascular endothelial growth factor-containing therapy on survival in patients with metastatic colorectal cancer: Data from the PRIME study (2013) (2)
- Resection after chemotherapy (CT) with irinotecan (CPT) for initially unresectable liver metastasis (LM) from colorectal cancer (CRC) (2004) (2)
- Understanding the Value of Response and Early Tumour Shrinkage (ETS) in Pts with Wt kras MCRC Treated with Panitumumab (P) Plus Folfox (F) (2012) (2)
- Navelbine: The European experience in non small cell lung carcinoma (NSCLC) (1994) (2)
- Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer (2019) (2)
- Adjuvant chemotherapy of non-small-cell lung cancer (2013) (2)
- Masitinib plus irinotecan for second line treatment of esophagogastric adenocarcinoma: An open label phase Ib/II trial. (2015) (2)
- Efficacy and safety of FOLFIRINOX in patients with pancreatic metastatic cancer. (2013) (2)
- Prospective pharmacogenetic analysis in advanced colorectal cancer (CRC) patients receiving first-line cetuximab-UFT-irinotecan therapy: Importance of gene polymorphisms related to antibody-dependent cellular cytotoxicity (ADCC). (2016) (2)
- PD-0024OVERALL SURVIVAL (OS) AND TUMOUR SHRINKAGE OUTCOMES IN PATIENTS WITH SYMPTOMATIC/ASYMPTOMATIC METASTATIC COLORECTAL CANCER (MCRC): DATA FROM THE PRIME STUDY (2013) (2)
- P-149Impact of sequence of biologic therapies on overall survival (OS) in patients with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC): an exploratory, retrospective pooled analysis (2016) (2)
- Monoclonal antibodies and their fragments in cancer treatment (1998) (1)
- [Immunoscintigraphy and radioimmunotherapy of transplanted pancreatic carcinoma. Experimental animal studies with 131I-labeled monoclonal antibodies against CA 19-9, CEA and CA 125]. (1985) (1)
- Humoral and cellular responses of colorectal cancer patients treated with monoclonal antibodies and interferon gamma. (1990) (1)
- The PRIME trial: Quality-adjusted survival in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line therapy with panitumumab plus FOLFOX versus FOLFOX alone. (2015) (1)
- Prime study : a randomised phase 3 study of panitumumab with Folfox4 versus Folfox4 alone as first line treatment for metastatic colorectal cancer (mCRC) (2010) (1)
- Cost-effectiveness of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting (2006) (1)
- Effect of Post-Protocol Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal AntiBody (MAB) Therapy on Survival Outcomes in Patients with Wild-Type (WT) Kras Metastatic Colorectal Cancer (MCRC) Treated with Panitumumab (PMAB) Plus Chemotherapy (2012) (1)
- FOLFIRINOX in first-line metastatic pancreatic cancer regimen (FLMPC): What profile of patients take a real advantage? Real world cohort from cancer observatory from Brittany and Pays de la Loire areas. (2014) (1)
- Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer. (2001) (1)
- O-0031EVALUATION OF KRAS, NRAS, AND BRAF MUTATIONS IN PRIME: PANITUMUMAB WITH FOLFOX4 AS FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER (MCRC) (2013) (1)
- Cost-effectiveness of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting. (2006) (1)
- 167OPROGNOSTIC AND PREDICTIVE BIOMARKERS FOR ACT (ADJUVANT CHEMOTHERAPY) IN RESECTED NON-SMALL CELL LUNG CANCER (R-NSCLC): LACE-BIO. (2014) (1)
- PD-0004THE PRIME STUDY: SURVIVAL OUTCOMES IN PATIENTS WITH KRAS/NRAS WILD-TYPE METASTATIC COLORECTAL CANCER AND NON-LIVER-LIMITED DISEASE (2014) (1)
- Identification and characterization of a rat protein (P 105) auto‐antigenic in rats bearing a progressive syngeneic colon carcinoma (1992) (1)
- O-085 Phase III trial of the protein kinase C α (PKCα) antisense oligonucleotide Aprinocarsen plus gemcitabine/cisplatin versus gemcitabine/cisplatin alone in advanced stage non-small cell lung cancer (NSCLC): Updated results of a randomized phase III trial (2005) (1)
- 6143 POSTER Study 20050203/PRIME – Effect of Post-Progression Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody (mAb) Therapy in Patients With Wild-Type (WT) KRas Metastatic Colorectal Cancer (mCRC) (2011) (1)
- P-453 Phase I and pharmacokinetic study of the combination ofvinflunine (VFL) and gemcitabine (GEM) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts) (2005) (1)
- Importance of tumour symptoms and extent of disease on efficacy of first-line FOLFOX4 ± panitumumab (pmab) in patients (pts) with RAS wild-type (WT)/BRAF WT metastatic colorectal cancer (mCRC) in the PRIME study (2016) (1)
- Randomized phase III placebo-controlled trial of carboplatin/paclitaxel (CP) with or without the vascular-disrupting agent vadimezan (ASA404) in advanced non-small cell lung cancer (NSCLC). (2011) (1)
- Is panitumumab monotherapy safe in metastatic colorectal cancer patients over 70 years old (2015) (1)
- 2139 Chemotherapy followed by a combination of daily irradiation and carboplatine (CBDCA) in stage IIIB non small cell lung cancer (NSCLC): First interim analysis of a phase II trial (1996) (1)
- Body mass index (BMI) as prognostic in metastatic colorectal cancer (mCRC): A pooled analysis of 21 first-line trials in the ARCAD database. (2014) (1)
- PD-013A study level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors (EGFRIs) vs bevacizumab in patients with metastatic colorectal cancer (mCRC) (2015) (1)
- Efficacy and safety of panitumumab in a cohort of patients with metastatic colorectal cancer in France: PANI OUEST, a post-EMA-approval descriptive study with a geriatric oncology focus. (2020) (1)
- Oncology and public health (2012) (1)
- A case for time to tumor progression (TTP) as the primary (1o) efficacy endpoint in 1st-line metastatic colorectal cancer (MCRC) therapy: Correlation of TTP and overall survival (OS) (2004) (1)
- EGFR Expression Is Unreliable to Decide for Cetuximab Treatment in Patients with Metastatic Colorectal Cancer: Results from “ERBITUX-OUEST” (2016) (1)
- [Small cell carcinoma of the esophagus. Report of five cases with review of the literature]. (1997) (1)
- Change in CEA as an early predictor of progression to first-line systemic therapy in metastatic colorectal cancer. (2018) (1)
- Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? (2008) (1)
- Resection after chemotherapy (CT) with irinotecan (CPT) for initially unresectable liver metastasis (LM) from colorectal cancer (CRC). (2004) (1)
- Evaluation of lesion-based response at 12 weeks (LBR12) of treatment (Rx) in metastatic colorectal cancer (mCRC): Findings from 9,092 patients (pts) in the ARCAD database. (2018) (1)
- 6074 Bevacizumab (bev) combined with chemotherapy as 2nd-line treatment for metastatic colorectal cancer (mCRC): results from the phase II BEVACOLOR study (2009) (1)
- 352 Induction chemotherapy (ICT cisplatin and vinorelbine) followed by a combination of daily irradiation and carboplatine (CBDCA) in stage IIIB non small cell lung cancer (NSCLC): Final analysis of a phase II trial (1997) (1)
- [Preliminary results of cytotoxic monoclonal antibody treatment in pancreatic adenocarcinomas and biliary tract carcinomas]. (1990) (1)
- Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics (2014) (1)
- Gastrointestinal tumors, colorectal (2012) (1)
- Safety analysis of the French Intergroup R98 trial comparing 5FU-leucovorin alone or with irinotecan in resected stages II-III rectal cancers (2008) (1)
- 861P Limited implementation of the ESMO-ESGO (European Society of Gynaecological Oncology)-ESTRO (European Society for Radiotherapy and Oncology) consensus conference recommendations (CCR) on endometrial cancer (EC) (2020) (1)
- RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. (2018) (1)
- 3603 Management of unresectable metastatic colorectal cancer (MRCC) in the real world with successive regimens with targeted therapies (Bevacizumab and cetuximab): the experience of the OMIT Bretagne Pays de Loire (2009) (1)
- Non-small-cell lung cancer: should histology guide chemotherapy treatment? (2009) (1)
- Efficacity and safety of panitumumab in mCRC patients: A post-AMM OMIT study. (2012) (1)
- Gastrointestinal tumors, colorectal (2012) (1)
- Panitumumab as a single agent in 269 metastatic colorectal cancer patients in the real practice: A post EMA approval study. (2012) (1)
- [Experimental model for metastasis of cecal origin]. (1991) (1)
- [Monoclonal antibodies in the diagnosis and treatment of hepatic metastases of colo-rectal cancers]. (1985) (1)
- 30 Nintedanib (BIBF 1120) + docetaxel as second-line therapy in patients with stage IIIB/IV or recurrent NSCLC: results of the phase III, randomised, double-blind LUME-Lung 1 trial (2014) (0)
- 354 Efficacy of induction chemotherapy (ICT) before concomitant chemoradiotherapy (CRCT) is predictive of local control and survival in unresectable locally advanced non small cell lung cancer (NSCLC) (1997) (0)
- Reply to the letter to the editor 'ESMO-MCBS v1.1: statistical and patient relevant shortcomings' by Emprechtinger et al. (2018) (0)
- O-0014 Effect of Post-Protocol anti-EGFR mAb Therapy on Survival Outcomes in Patients with Wild-Type Kras MCRC Treated with Panitumumab Plus Chemotherapy (2012) (0)
- Implementing clinical practice guidelines: time to assess it (2020) (0)
- 1095 A phase II study of CPT 11 (irinotecan 350mg/m2 every 3 weeks) in untreated non-small cell lung carcinomas (1995) (0)
- 1438O_PRReport on ESMO/SIOPE European Landscape project key results: Mapping the status and needs in AYA cancer care (2017) (0)
- Traitements adjuvants post-opératoires (1999) (0)
- [Radiopharmacokinetic study, in nude mice, of monoclonal antibodies specific for human gastrointestinal cancers]. (1983) (0)
- 3102 Tumour growth over time in patients with advanced non-small cell lung cancer treated with nintedanib plus docetaxel or placebo plus docetaxel: Analysis of data from the LUME-Lung 1 study (2015) (0)
- 6127 POSTER What About Risk Factors KRAS, BRAF and PI3K in a French Translational Study OMIT of 325 Patients Traited With Cetuximab Based-regimen in Real Practice (2011) (0)
- PD-024Retrospective analysis of quality of life and early tumour shrinkage during first-line FOLFOX4 ± panitumumab in RAS wild-type metastatic colorectal carcinoma (2016) (0)
- [Management of non-small-cell bronchial cancers. Postoperative adjuvant treatments]. (1999) (0)
- Reply to the letter to the editor 'Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies'. (2017) (0)
- 1 3-Fluoro-and 3 , 3-Difluoro-3 , 4-dideoxy-KRN 7000 Analogues as New 2 Potent Immunostimulator Agents : Total Synthesis and Biological 3 Evaluation in Human Invariant Natural Killer T Cells and Mice (2012) (0)
- [Immunohistochemical study with monoclonal antibodies specific for human gastrointestinal cancers]. (1983) (0)
- P-308RAVELLO trial: Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (2015) (0)
- Outcome of patients malnourished at diagnosis of a metastatic lung adenocarcinoma. (2014) (0)
- [Characterization of autoantigen (p105) in a model of colonic adenocarcinoma in the rat]. (1992) (0)
- Chromothripsis in Uterine Leiomyomas (2013) (0)
- Pharmacokinetic (PK) and tolerance profiles of oral tegafur/uracil (UFT) given as three versus two daily intakes. (2006) (0)
- [Immuno-scintigraphy in the diagnosis of distal bone metastasis of colonic cancer]. (1994) (0)
- Abstract 2559: Optimisation of EGFR TKI efficiency wild-type EGFR lung cancer (2015) (0)
- Acknowledgement to the Reviewers (2007) (0)
- [Use of antibodies or their fragments for the treatment of tumors]. (1998) (0)
- MC13-0021 Impact of post-protocol anti-epidermal growth factor receptor therapy on survival in wild-type KRAS/NRAS metastatic colorectal cancer: Data from the PRIME study (2013) (0)
- Evaluating gender as a predictive marker for response to bevacizuamb (Bev) in metastatic colorectal carcinoma (mCRC): Pooled analysis of 3369 patients (pts) in the ARCAD database. (2019) (0)
- Panitumumab (PMAB) in combination with chemotherapy (CT) versus CT alone: health-related quality of life (HRQOL) in patients (PTS) with wild-type (WT) KRAS metastatic colorectal cancer (MCRC) (2011) (0)
- Toward Improved Outcomes for Patients With Lung Cancer Globally: The Essential Role of Radiology and Nuclear Medicine (2022) (0)
- Expression of blood group-related glycosidic tissue antigens on regressive and progressive variants of a rat colon carcinoma. (1990) (0)
- [New prospects in the treatment of non-small-cell lung carcinoma (NSCLC): new biological factors]. (2001) (0)
- ESMO Copenhagen 2016: a lung cancer ‘grand cru’ (2017) (0)
- Can interleukin-2 reverse anthracyclin chemoresistance in metastatic soft tissue sarcomas? Results of a prospective clinical phase II trial. (2001) (0)
- 519POutcomes in patients receiving maintenance therapy in two panitumumab (Pmab) first-line trials for metastatic colorectal cancer (mCRC) (2017) (0)
- Ayurveda — For Optimal Health and Well-Being (2004) (0)
- Efficacy of first-line modified FOLFOX6 with panitumumab or bevacizumab in RAS wild-type/BRAF wild-type metastatic colorectal cancer: impact of tumour symptoms and extent of disease (2016) (0)
- Adolescents and young adults with cancer care in Asia: The joint ESMO/SIOPE/SIOP ASIA survey. (2018) (0)
- 250PEGFR TESTING FROM CIRCULATING CELL-FREE DNA: READY FOR ROUTINE PRACTICE. (2014) (0)
- Quality of life assessment during clinical trials: Application to the multicentre phase II study of fotemustine in advanced non small cell lung carcinoma (NSCLC) (1993) (0)
- Reply to the letter to the editor 'Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?' by Del Paggio. (2018) (0)
- ORA cover sheet (2018) (0)
- A.N.I.T.A. (Adjuvant Navelbine International Trialist Association). A possible solution to the unresolved issues in adjuvant therapy for resectable non-small cell lung cancer (NSCLC) (1998) (0)
- PCN3 Quality-Adjusted Survival in Patients With Wild-Type (WT) KRASs Metastatic Colorectal Cancer (mCRC) Receiving First-Line Therapy With Panitumumab Plus FOLFOX Versus FOLFOX Alone (2012) (0)
- Analysis of the role of RAS Family Mutations in Metastatic Colorectal Cancer (mCRC): Current Treatment Practice (2014) (0)
- Associations between dermatologic toxicity severity, patient characteristics, and efficacy among patients treated with panitumumab (Pmab) and chemotherapy (2016) (0)
- PD-028Retrospective analysis of impact of Köhne prognostic category and BRAF mutation status on survival in patients with RAS wild-type metastatic colorectal cancer treated with second-line FOLFIRI with/without panitumumab (2016) (0)
- Phase II study of IV Vinflunine (VFL) as second line treatment of patients (pts) with advanced non-small-cell lung cancer (NSCLC) previously treated with a platinum based regimen. Final results. (2004) (0)
- Relationship Between EGFR Expression Level, EGFR Mutation Status and the Efficacy of Chemotherapy Plus Cetuximab in Flex Study Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) (2012) (0)
- Treatment effects (TEs) of EGFR monoclonal antibodies (mAbs) in metastatic colorectal cancer (mCRC) patients (pts) with KRAS, NRAS, and BRAF mutation (MT) status: Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database. (2020) (0)
- Contents Vol. 68, 2005 (2005) (0)
- [Chemotherapy of stage IV non-small-cell bronchial cancer]. (2001) (0)
- 5FU/LV with or without irinotecan in patients with resected stage II-III rectal cancer: Final analysis of R98 intergroup study. (2013) (0)
- [Targeted therapies in thoracic oncology]. (2004) (0)
- A phase II trial of radio-chemotherapy with daily carboplatin, after induction chemotherapy (cisplatin and vinorelbine), in locally advanced non-small-cell lung cancer (LANSCLC): final analysis (1998) (0)
- Nmr relaxation time in nude mice bearing human colorectal adenocarcinoma injected with monoclonal antibody 19.9 coupled with gadolinum diethylenetriaminepentaacetic acid as contrast agent (1985) (0)
- [Standards, Options and Recommendations for the management of stage I or II primary bronchial cancers treated exclusively with radiotherapy]. (2001) (0)
- Gefitinib plus docetaxel in non-small-cell lung cancer – Authors' reply (2009) (0)
- Ayurveda — For Optimal (2004) (0)
- PD-0023 Benefit of Adding Panitumumab (pmab) To 1St/2Nd-Line Chemotherapy in Patients with KRAS WT mCRC: A Number-Needed-To-Treat (NNT) Analysis (2012) (0)
- Prospects for colorectal cancer treatment: oral chemotherapy and targeted biotherapy (2003) (0)
- Subject Index Vol. 68, 2005 (2005) (0)
- Standards, Options and Recommendations (SOR) for the perioperative treatment of operable patients with resecable non small cell lung cancer (update) (2007) (0)
- O-270 Final results of a randomized phase II sequential two-line study of docetaxel (D) + cisplatin (CDDP) vs vinorelbine (V) + CDDP followed by crossover at progression in stage IV non-small cell lung cancer (NSCLC) (2003) (0)
- Phase II pilot study of Ifosfamide-Cisplatine-Etoposide association as Neo-Adjuvant chemotherapy in locally advanced non-small cell lung cancers (1991) (0)
- IL3 Monoclonal antibodies in the treatment of non-small-cell lung cancer (2008) (0)
- Immunohistocytochemical Analysis of Gastrointestinal Carcinomas Using Immunoperoxidase and Immunogold Staining with Monoclonal Antibodies 19.9 and Anti CEA (1985) (0)
- Small cell carcinoma of the esophagus. Report of five cases with a literature review (1997) (0)
- 5FU-leucovorin (5FU/LV) with or without irinotecan (CPT-11) in stages II-III rectal cancers: Preliminary safety analysis of the French Intergroup R98 phase III trial. (2004) (0)
- Failure of monoclonal antibodies against tumor associated antigens to improve tumor targeting of LAK cells in a model of rat colon carcinoma. (1993) (0)
- Characterization of a rat colon carcinoma-specific Mr 66,000 protein (1990) (0)
- AVASTERB OUEST: A prospective cohort study of unresectable metastatic colon cancer treated successively by FOLFIRI bevacizumab and cetuximab irinotecan. (2016) (0)
- Quality-Adjusted Survival in Patients with Wild-Type (WT) Kras Metastatic Colorectal Cancer (MCRC) Receiving First-Line Therapy with Panitumumab Plus Folfox Versus Folfox Alone (2012) (0)
- 353 Combined chemoradiation therapy for locally advanced resectable non small cell lung cancer (NSCLC) (1997) (0)
- 358Early results of a large randomised trial of ‘tomudex’ (raltitrexed) versus 5-fluorouracil (5FU) plus high dose leucovorin (HDLV) in patients with advanced colorectal cancer (ACC) (1996) (0)
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer (2022) (0)
- 6517 ORAL Meta-analysis comparing docetaxel and vinca-alkaloids in the first-line treatment of NSCLC. Comparison of results based on individual patient data, study report data, and published data (2007) (0)
- Multi-Institutio nal R andomized P hase I I T rial o f G efitinib f or Previously T reated P atients W ith A dvanced N on-Small-Cell Lung C ancer (2003) (0)
- Panitumumab with FOLFOX4 versus FOLFOX4 alone as first-line treatment for metastatic colorectal cancer (mCRC): results from the randomised phase III PRIME study (2010) (0)
- [Inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase: similarity and differences]. (2011) (0)
- 9010 Impact of histology on survival in resected patients with Non Small Cell Lung Cancer (NSCLC): Subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation ANITA trial (2009) (0)
- 3070 POSTER Bevacizumab in patients with previously treated metastatic colorectal cancer: preliminary results of a phase II study (bevacolor) (2007) (0)
- OP-ANNO190436 1417..1427 (2019) (0)
- Interim efficacy analysis of the French Intergroup R98 trial comparing 5FU-leucovorin alone or with irinotecan (CPT-11) in resected stages II-III rectal cancers. (2009) (0)
- [Use of vinorelbine in non-small cell bronchial cancer: current aspects and perspectives]. (1996) (0)
- Nivolumab in non-small cell lung cancer: French evaluation of use, current practices and medico-economic approach. (2018) (0)
- Phase II study of fotermustine in the treatment of inoperable non small cell lung carcinoma (NSCLC): Finalreport (1993) (0)
- Interim report of a phase i study of docetaxel (Taxotere®) in combination with vinorelbine in chemotherapy naive patients with metastatic or inoperable non small cell lung cancer (NSCLC) (1997) (0)
- Endpoints in adjuvant trials: A systematic review of the literature in colon cancer and proposed definitions for future trials (2007) (0)
- Abstract A57: Extended RAS analysis in patients (pts) with untreated metastatic colorectal cancer (mCRC): Results from the PRIME and PEAK studies (2014) (0)
- Prognostic value of the number of examined lymph nodes in totally resected Non-Small-Cell Lung Cancer: PD5-3-2 (2007) (0)
- 78 Dose intensive chemotherapy in patients with advanced small cell lung cancer (SCLC): Preliminary results of a multicenter randomized trial (1995) (0)
- [Radiation therapy with 131I-MIBG is still relevant for metastatic carcinoid tumors]. (2005) (0)
- Practice of lung cancer health care in France (2000) (0)
- Phase II with Taxol® (Paclitaxel) (T), Carboplatin (C) and brain radiotherapy (RT) in patients (PTS) with inoperable brain metastases (BM) of non-small cell lung cancer (NSCLC) (2000) (0)
- Front & Back Matter (2013) (0)
- PD-0025 Evaluation of Codon 12 and 13 KRAS Mutations as Biomarkers of Response to Panitumumab in Patients with Metastatic Colorectal Cancer (2012) (0)
- ESMO Guidelines Committee. (2018) (0)
- 73P αGalCer/antibody complex targeting EGFR-tumor-associated iNKT to restore the immune response (2020) (0)
- PD5-3-2: Prognostic value of the number of examined lymph nodes in totally resected Non-Small-Cell Lung Cancer (2007) (0)
- 2349 Phase 1b/2 study results for masitinib plus irinotecan in second-line treatment of esophagogastric adenocarcinoma (2015) (0)
- Detection of EGFR alterations in circulating cell-free DNA of lung tumor patients: Higher sensitivity obtained with plasma compared to serum. (2013) (0)
- PD-026Survival outcomes in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) classified by Köhne prognostic category and BRAF mutation status: retrospective analysis of the PRIME study (2016) (0)
- P-136Evolution of efficacy and safety of cetuximab with the determination of RAS status in Metastatic Colorectal Cancer (mCRC) elderly patients (2016) (0)
- 21 Failure of GM-CSF supported dose intensification of a four-drug chemotherapy in extensive small cell lung cancer (SCLC), extended analysis of a phase III trial with determination of prognostic variables (1997) (0)
- The need for a new fluoropyrimidine in advanced gastric cancer treatment (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Jean‐yves Douillard?
Jean‐yves Douillard is affiliated with the following schools:
